Literature DB >> 26745326

Molecular Epidemiology and Drug Resistance of Acinetobacter baumannii Isolated from Hospitals in Southern Poland: ICU as a Risk Factor for XDR Strains.

Agnieszka Chmielarczyk1, Magdalena Pilarczyk-Żurek1, Wanda Kamińska2, Monika Pobiega1, Dorota Romaniszyn1, Grzegorz Ziółkowski3, Jadwiga Wójkowska-Mach1, Małgorzata Bulanda1.   

Abstract

The objectives of the present study were to investigate the carbapenemase and metallo-beta-lactamase genes of Acinetobacter baumannii clinical isolates by polymerase chain reaction (PCR) and real time PCR and to determine the molecular epidemiology of the strains using the DiversiLab tool. From these data, correlations between drug resistance, resistance genes, and epidemiological clones may be revealed. The study was conducted on 125 A. baumannii collected over the 2013 year. The majority of the isolates from both intensive care unit (ICU) and non-ICU cases originated from pneumonia infections (79.2%), isolates from blood infections accounted for 17.6% and 3.2% were from meningitis infections. In the ICU cases compared with the non-ICU cases, bloodstream infections were more frequently diagnosed (19.2% vs. 11.5%). Sixty percent of A. baumannii strains were resistant to all the antimicrobials tested with the exception of colistin. All strains were susceptible to colistin and polymyxin B. Extensively drug-resistant (XDR) strains accounted for 80.8% of the isolates tested and these XDR strains were more frequently isolated from ICU cases than from non-ICU cases (93.9% vs. 30.8%). Among the 101 isolates of A. baumannii exhibiting the XDR pattern of resistance, 80 possessed the blaOXA-24 gene and 29 had the blaOXA-23 gene. Only two isolates possessed the blaVIM gene. The presence of the ISAba1element was confirmed among 10 strains from patients hospitalized in the ICU. Using repetitive extragenic palindromic sequence PCR (DiversiLab typing), six clones and 12 unique strains were identified, of which two clones dominated. Most isolates belonging to clone 1 (66.7%) and clone 2 (85.5%) were susceptible only to colistin. In summary, it is clear from our findings and those of other studies that carbapenem resistance among A. baumannii strains presents a serious clinical problem worldwide. Furthermore, the presence of XDR international clone II in ICUs poses a potential risk for future outbreaks of A. baumannii infection and controlling A. baumannii infections in hospitals presents a serious challenge.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26745326     DOI: 10.1089/mdr.2015.0224

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  17 in total

1.  Healthcare-Acquired Infection Surveillance in Neurosurgery Patients, Incidence and Microbiology, Five Years of Experience in Two Polish Units.

Authors:  Elżbieta Rafa; Małgorzata Kołpa; Marta Zofia Wałaszek; Adam Domański; Michał Jan Wałaszek; Anna Różańska; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2022-06-20       Impact factor: 4.614

2.  Pharmacokinetic and Pharmacodynamic Profiling of Minocycline for Injection following a Single Infusion in Critically Ill Adults in a Phase IV Open-Label Multicenter Study (ACUMIN).

Authors:  Thomas P Lodise; Scott Van Wart; Zoe M Sund; Adam M Bressler; Akram Khan; Amy T Makley; Yasir Hamad; Robert A Salata; Fernanda P Silveira; Matthew D Sims; Badih A Kabchi; Mohamed A Saad; Carrie Brown; Randolph E Oler; Vance Fowler; Richard G Wunderink
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

3.  Incidence, Microbiological Profile and Risk Factors of Healthcare-Associated Infections in Intensive Care Units: A 10 Year Observation in a Provincial Hospital in Southern Poland.

Authors:  Małgorzata Kołpa; Marta Wałaszek; Agnieszka Gniadek; Zdzisław Wolak; Wiesław Dobroś
Journal:  Int J Environ Res Public Health       Date:  2018-01-11       Impact factor: 3.390

4.  Multi-locus sequence typing (MLST) of non-fermentative Gram-negative bacilli isolated from bloodstream infections in southern Poland.

Authors:  Agnieszka Chmielarczyk; Monika Pobiega; Dorota Romaniszyn; Jadwiga Wójkowska-Mach
Journal:  Folia Microbiol (Praha)       Date:  2017-09-22       Impact factor: 2.099

5.  Patient as a Partner in Healthcare-Associated Infection Prevention.

Authors:  Marta Wałaszek; Małgorzata Kołpa; Zdzisław Wolak; Anna Różańska; Jadwiga Wójkowska-Mach
Journal:  Int J Environ Res Public Health       Date:  2018-03-29       Impact factor: 3.390

6.  Identification of Selected Antibiotic Resistance Genes in Two Different Wastewater Treatment Plant Systems in Poland: A Preliminary Study.

Authors:  Magdalena Pazda; Magda Rybicka; Stefan Stolte; Krzysztof Piotr Bielawski; Piotr Stepnowski; Jolanta Kumirska; Daniel Wolecki; Ewa Mulkiewicz
Journal:  Molecules       Date:  2020-06-20       Impact factor: 4.411

7.  Antibiotic consumption and antimicrobial resistance in Poland; findings and implications.

Authors:  Jadwiga Wojkowska-Mach; Tomasz Bochenek; Brian Godman; Amanda Glassman; Amanj Kurdi; Andrzej Pilc; Anna Rozanska; Szymon Skoczyński; Marta Wałaszek
Journal:  Antimicrob Resist Infect Control       Date:  2018-11-15       Impact factor: 4.887

Review 8.  Insight into Acinetobacter baumannii: pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities.

Authors:  Muhammad Asif; Iqbal Ahmad Alvi; Shafiq Ur Rehman
Journal:  Infect Drug Resist       Date:  2018-08-21       Impact factor: 4.003

9.  Epidemiology of Ventilator-Associated Pneumonia, microbiological diagnostics and the length of antimicrobial treatment in the Polish Intensive Care Units in the years 2013-2015.

Authors:  Michał Wałaszek; Anna Różańska; Marta Zofia Wałaszek; Jadwiga Wójkowska-Mach
Journal:  BMC Infect Dis       Date:  2018-07-06       Impact factor: 3.090

10.  Antimicrobial effect of copper alloys on Acinetobacter species isolated from infections and hospital environment.

Authors:  Anna Różańska; Agnieszka Chmielarczyk; Dorota Romaniszyn; Grzegorz Majka; Małgorzata Bulanda
Journal:  Antimicrob Resist Infect Control       Date:  2018-01-22       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.